Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Genomics and AI identify a candidate gene behind rare neurodevelopmental disorder

28

Sep 2026

Genomics and AI identify a candidate gene behind rare neurodevelopmental disorder

Researchers at Baylor College of Medicine, the Duncan Neurological Research Institute (Duncan NRI) at Texas Children's Hospital, the Texome Project and collaborating institutions have identified variants in gene BRSK1 as a likely diagnosis for individuals with a rare and complex neurodevelopmental disorder who until now had not received an explanation for their condition.

Intentional substance exposures at school rise sharply among younger children

28

Sep 2026

Intentional substance exposures at school rise sharply among younger children

A new study found that rates of intentional substance exposures at school reported to U.S. poison centers increased substantially among elementary- and middle-school-aged children from 2000 through 2024, while high-school-aged adolescents continued to experience the highest rates of serious medical outcomes and hospital admissions.

New artificial intelligence model detects tissue damage in the heart

28

Sep 2026

New artificial intelligence model detects tissue damage in the heart

Researchers from the COR group at the Institute of Information and Communications Technologies (ITACA) of the Universitat Politècnica de València (UPV) have developed an artificial intelligence model capable of localizing and quantifying tissue abnormalities associated with atrial cardiomyopathy using electrical recordings from the body's surface.

New study links human reaction times to breathing cycles

28

Sep 2026

New study links human reaction times to breathing cycles

Imagine swimmers on starting blocks poised to dive at the sound of the starting horn or the driver of a car going 60 mph suddenly needing to brake to avoid a collision. A small fraction of a second in response time could make the difference between winning or losing and life or death.

Fractionated radiosurgery extends survival for brain metastasis patients

28

Sep 2026

Fractionated radiosurgery extends survival for brain metastasis patients

Delivering focused radiation therapy over three to five sessions after surgery for a large brain metastasis reduced the risk of cancer returning at the surgical site compared with delivering the radiation in a single session, according to the results of the Alliance for Clinical Trials in Oncology A071801 presented today at the plenary session of the American Society for Radiation Oncology in Boston.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.